resources

Piramal Pharma Ltd.

NSE: PPLPHARMA

BSE: 543635

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

226.62+7.0 (+3.17%)

8 Sep, 12:00 AM

Overview Analysis Statements Technicals Forecast Peers Resources

News

Annual Reports and Financial Documents

Piramal Pharma Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

	2022	2023	2024	2025	2026
Annual Reports	—	FY 2023	FY 2024	FY 2025	FY 2026
Quarterly Results	Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun
Conference Calls	11Nov	13Feb 18May 29May 7Aug 7Aug 31Oct	2Feb 14May 29Jul 26Oct	30Jan 30Jan 16May 31Jul 7Nov	30Jan 30Apr 31Jul
Presentations	—	5Jan 24May 3Aug 27Oct	30Jan 10May 26Jul 24Sept 23Oct	28Jan 14May 28Jul 5Nov	29Jan 28Apr 29Jul

Corporate Announcements and Regulatory Filings

Piramal Pharma Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.

Analyst / Investor Meet8 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please refer attached file
General3 Sept 2026
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
Please refer attached file
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201126 Aug 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
General24 Aug 2026
Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26
Please refer attached file
Acquisition18 Aug 2026
Announcement under Regulation 30 (LODR)-Acquisition
Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201118 Aug 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
General10 Aug 2026
Announcement Under Regulation 30 (LODR)- Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private Limited
Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited
Analyst / Investor Meet10 Aug 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
General3 Aug 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -Resumption Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat
Please refer attachment
AGM30 Jul 2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM
AGM30 Jul 2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings and Voting Results of the 6th Annual General Meeting of the Company
Analyst / Investor Meet30 Jul 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find enclosed intimation of audio recordings of the conference call held today 30th July, 2026.
Press Release / Media Release29 Jul 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please see enlcosed Press Release for Q1 FY 27
Outcome of Board Meeting29 Jul 2026
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 29Th July, 2026
Please find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July, 2026
General29 Jul 2026
Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Grant Of Stock Options
Grant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Incentive Plan 2022
General24 Jul 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Temporary Suspension Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat.
Please refer attachment.
Analyst / Investor Meet20 Jul 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.
Board Meeting20 Jul 2026
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June, 2026.
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201117 Jul 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
General9 Jul 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Successful closure of US FDA Inspection at Piramal Pharma''s manufacturing facility located at Sellersville (USA) facility

Frequently Asked Questions

Where can I download the annual report of Piramal Pharma Ltd.?

Annual reports of Piramal Pharma Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.

Where can I find the quarterly results of Piramal Pharma Ltd.?

Quarterly earnings results and presentations of Piramal Pharma Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.

Does Piramal Pharma Ltd. publish earnings call transcripts?

Earnings call transcripts of Piramal Pharma Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.

Where can I find investor presentations of Piramal Pharma Ltd.?

Investor presentations and annual day presentations of Piramal Pharma Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.

What are the recent corporate announcements of Piramal Pharma Ltd.?

Corporate announcements and regulatory filings of Piramal Pharma Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.

How do I access the regulatory filings of Piramal Pharma Ltd.?

Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Piramal Pharma Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.

What is the ISIN of Piramal Pharma Ltd.?

The ISIN (International Securities Identification Number) of Piramal Pharma Ltd. is INE0DK501011. This is the unique identifier used across exchanges and depositories.

On which stock exchange is Piramal Pharma Ltd. listed?

Piramal Pharma Ltd. is listed on NSE and BSE. The NSE symbol is PPLPHARMA and the BSE code is -.

Where can I find the shareholding pattern of Piramal Pharma Ltd.?

The quarterly shareholding pattern of Piramal Pharma Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.

How current is the data for Piramal Pharma Ltd. on Sharpely?

Share price data for Piramal Pharma Ltd. is updated as of 8 Sep 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.